CSL strikes USD 355 million deal. CSL stock gains 1.57 percent

Published on 10/09/2026 at 12:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CSL stock costs EUR 114.04 on October 9, 2026 after EUR 112.28, plus 1.57 percent. The deal includes USD 1.2 billion in milestones.

Key points in brief

CSL agreed to pay USD 355 million upfront for a global lixudebart partnership with Alentis on October 5, 2026.
The deal includes up to USD 1.2 billion in commercial milestones and gives CSL 55 percent of global profits.
CSL stock was at EUR 114.04 at Lang & Schwarz on October 9, 2026, plus 1.57 percent versus the prior close.

CSL, AU000000CSL8, Illustration mit AI erstellt.

CSL Limited stock (ISIN AU000000CSL8) was trading at EUR 114.04 at Lang & Schwarz on October 9, 2026, up 1.57 percent versus the prior close. On October 5, 2026, CSL agreed to pay USD 355 million upfront in an exclusive global partnership with Alentis for lixudebart, according to Alentis Therapeutics.

Three milestones reshape the pipeline

On June 18, 2026, CSL reported U.S. regulatory approval for ANDEMBRY, with a Phase 3 study showing an 89.20 percent reduction in hereditary angioedema attacks versus placebo, as documented by Simply Wall St. On July 28, 2026, CSL reported positive Phase 3b results for children aged 2 to 11, with 22 participants in the study, according to the same Simply Wall St.

The October 5 partnership is the latest step, adding a Phase 2 kidney program and planned Phase 3 work in AAV-RPGN, alongside planned studies in FSGS and PSC. Alentis can receive up to USD 1.2 billion in commercial milestones, while CSL would receive 55 percent of worldwide commercialization profits, according to Alentis Therapeutics. The trade-off is clear: CSL gets development rights and majority profit participation, but it also funds the ongoing and planned trials.

What does the deal add to CSL?

Lixudebart is being evaluated in a Phase 2 trial for AAV-RPGN, a rare autoimmune kidney disease, and the program is intended to expand into kidney and liver indications. That gives CSL a new pipeline asset beyond its established plasma therapies, vaccines and specialty medicines.

Dates for the next milestones

CSL's 2026 annual general meeting is scheduled for October 27, 2026, according to CSL. The company is also scheduled to report first-half 2027 results on February 10, 2027, according to Simply Wall St.

CSL stock trades above EUR 114

CSL was trading at EUR 114.04 at Lang & Schwarz on October 9, 2026 at 12:10 p.m. CEST, plus 1.57 percent versus the Lang & Schwarz prior close of EUR 112.28 on October 8, 2026. On the ASX, CSL was last at AUD 183.84 on October 9, 2026 at 4:12 p.m. AEDT, while its 52-week range was AUD 90.00 to AUD 222.47 and its market capitalization was AUD 88.0 billion. The further course of trading is shown by the continuously updated real-time quote of CSL stock.